Assessing the potential of pharmaceuticals and their transformation products to cause mutagenic effects: Implications for gene expression profiling

Medicine & Life Sciences

• Gene Expression Profiling 88%
• Pharmaceutical Preparations 35%
• Spliceosomes 23%
• Atenolol 21%
• Metoprolol 21%
• Ofloxacin 21%
• Azithromycin 20%
• Ibuprofen 20%
• Diclofenac 20%
• Carbamazepine 19%
• Sulfamethoxazole Drug Combination Trimethoprim 19%
• p53 Genes 18%
• Erythromycin 18%
• Aspartic Acid 17%
• Alanine 17%
• Propranolol 17%
• Mitogen-Activated Protein Kinases 17%
• Transcriptome 15%
• Mass Spectrometry 15%
• Glutamic Acid 15%
• Phosphotransferases 13%
• Gene Expression 10%
• Health 8%

Earth & Environmental Sciences

• gene expression 100%
• drug 69%
• mutagenicity 63%
• assay 43%
• product 41%
• effect on the environment 21%
• effect 19%
• prioritization 18%
• integrated approach 17%
• mass spectrometry 14%
• metabolism 14%
• human health 13%
• gene 13%
• protein 12%
• liquid 10%

Chemical Compounds

• Pharmaceutical 62%
• Chemical Transformation 53%
• Mixture 37%
• Azithromycin 21%
• Metoprolol 20%
• Atenolol 19%
• Trimethoprim 19%
• Ofloxacin 19%
• Erythromycin 18%
• Sulfamethoxazole 18%
• Carbamazepine 17%
• Diclofenac 17%
• Propranolol 17%
• Ibuprofen 16%
• Aspartate 15%
• Microarrays 15%
• Alanine 13%
• Pharmacological Metabolism 11%
• Environment 8%
• Liquid 7%
• Protein 5%